Literature DB >> 33828143

An EAV-HP insertion in the promoter region of SLCO1B3 has pleiotropic effects on chicken liver metabolism based on the transcriptome and proteome analysis.

Jianfei Chen1, Guoying Hua1, Deping Han2, Xiaotong Zheng1, Xianggui Dong1, Shuxiang Wang1, Junjiang Long3, Zhonghua Zheng3, Ailing Wang3, Jiankui Wang1, Xiaotong Wang4, Xuemei Deng5.   

Abstract

Solute carrier organic anion transporter 1B3 (SLCO1B3) is an important liver primarily highly expressed gene, its encoded protein (OATP1B3) involved in the transport of multi-specific endogenous and exogenous substances. We previously reported that an EAV-HP inserted mutation (IM+) in the 5' flanking region of SLCO1B3 was the causative mutation of chicken blue eggs, and a further research showed that IM+ significantly reduced the expression of SLCO1B3 in liver. Herein, we confirmed a cholate response element (IR-1) played an important role in activating SLCO1B3 and in vitro experiments showed that the activation of IR-1 can be significantly reduced by the EAV-HP IM+ . We performed transcriptome and proteomic analysis using the same set of IM+ and IM- liver tissues from Yimeng hens (a Chinese indigenous breed) to study the effect of SLCO1B3 and OATP1B3 expression reduction on chicken liver function. The results showed that common differential expression pathways were screened out from both transcriptome and proteome, in which fatty acid metabolism and drug metabolism-cytochrome P450 were significantly enriched in the KEGG analysis. The lipid-related metabolism was weakened in IM+ group, which was validated by serum biochemical assay. We unexpectedly found that EAV-HP fragment was highly expressed in the liver of the IM+ chickens. We cloned the EAV-HP full-length transcript and obtained the complete open reading frame. It is worth noting that there was some immune related differential expressed genes, such as NFKBIZ, NFKBIA, and IL1RL1, which were higher expressed in the IM+ group, which may due to the high expression of EAV-HP. Our study showed that EAV-HP IM+ reduced the expression of SLCO1B3 in liver, resulting in the decrease of fatty metabolism and exogenous substance transport capacity. The mutation itself also expressed in the liver and may be involved in the immune process. The mechanism needs further study.

Entities:  

Year:  2021        PMID: 33828143     DOI: 10.1038/s41598-021-87054-9

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  49 in total

1.  Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells.

Authors:  Kathrin Kopplow; Katrin Letschert; Jörg König; Bettina Walter; Dietrich Keppler
Journal:  Mol Pharmacol       Date:  2005-07-26       Impact factor: 4.436

2.  Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel.

Authors:  Nicola F Smith; Milin R Acharya; Neil Desai; William D Figg; Alex Sparreboom
Journal:  Cancer Biol Ther       Date:  2005-08       Impact factor: 4.742

3.  Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.

Authors:  Richard H Ho; Rommel G Tirona; Brenda F Leake; Hartmut Glaeser; Wooin Lee; Christopher J Lemke; Yi Wang; Richard B Kim
Journal:  Gastroenterology       Date:  2006-03-06       Impact factor: 22.682

4.  Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver.

Authors:  Evita van de Steeg; Viktor Stránecký; Hana Hartmannová; Lenka Nosková; Martin Hřebíček; Els Wagenaar; Anita van Esch; Dirk R de Waart; Ronald P J Oude Elferink; Kathryn E Kenworthy; Eva Sticová; Mohammad al-Edreesi; A S Knisely; Stanislav Kmoch; Milan Jirsa; Alfred H Schinkel
Journal:  J Clin Invest       Date:  2012-01-09       Impact factor: 14.808

5.  Recessive inheritance of population-specific intronic LINE-1 insertion causes a rotor syndrome phenotype.

Authors:  Tatehiro Kagawa; Akira Oka; Yoshinao Kobayashi; Yoichi Hiasa; Tsuneo Kitamura; Hiroshi Sakugawa; Yukihiko Adachi; Kazuya Anzai; Kota Tsuruya; Yoshitaka Arase; Shunji Hirose; Koichi Shiraishi; Takashi Shiina; Tadayuki Sato; Ting Wang; Masayuki Tanaka; Hideki Hayashi; Noboru Kawabe; Peter N Robinson; Tomasz Zemojtel; Tetsuya Mine
Journal:  Hum Mutat       Date:  2015-03       Impact factor: 4.878

6.  The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3.

Authors:  Annick Seithel; Sonja Eberl; Katrin Singer; Daniel Auge; Georg Heinkele; Nadine B Wolf; Frank Dörje; Martin F Fromm; Jörg König
Journal:  Drug Metab Dispos       Date:  2007-02-12       Impact factor: 3.922

Review 7.  Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family.

Authors:  B Hagenbuch; C Gui
Journal:  Xenobiotica       Date:  2008-07       Impact factor: 1.908

8.  Organic anion transporting polypeptides (OATP) in zebrafish (Danio rerio): Phylogenetic analysis and tissue distribution.

Authors:  Marta Popovic; Roko Zaja; Tvrtko Smital
Journal:  Comp Biochem Physiol A Mol Integr Physiol       Date:  2009-11-25       Impact factor: 2.320

Review 9.  Individualized pharmacotherapy with paclitaxel.

Authors:  Stephan Mielke
Journal:  Curr Opin Oncol       Date:  2007-11       Impact factor: 3.645

10.  Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia.

Authors:  Serena Sanna; Fabio Busonero; Andrea Maschio; Patrick F McArdle; Gianluca Usala; Mariano Dei; Sandra Lai; Antonella Mulas; Maria Grazia Piras; Lucia Perseu; Marco Masala; Mara Marongiu; Laura Crisponi; Silvia Naitza; Renzo Galanello; Gonçalo R Abecasis; Alan R Shuldiner; David Schlessinger; Antonio Cao; Manuela Uda
Journal:  Hum Mol Genet       Date:  2009-05-06       Impact factor: 6.150

View more
  1 in total

1.  WGCNA Analysis of Important Modules and Hub Genes of Compound Probiotics Regulating Lipid Metabolism in Heat-Stressed Broilers.

Authors:  Lihuan Zhang; Xuan Liu; Hao Jia
Journal:  Animals (Basel)       Date:  2022-10-01       Impact factor: 3.231

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.